StockNews.com Begins Coverage on BeiGene (NASDAQ:BGNE)

Equities research analysts at StockNews.com started coverage on shares of BeiGene (NASDAQ:BGNE) in a note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Other research analysts also recently issued reports about the stock. TD Cowen lifted their price target on shares of BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Morgan Stanley reissued an “overweight” rating and issued a $300.00 price target on shares of BeiGene in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. upped their price target on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, BeiGene presently has an average rating of “Moderate Buy” and an average target price of $253.69.

BeiGene Price Performance

BeiGene has a one year low of $126.97 and a one year high of $248.16. The stock has a market capitalization of $18.03 billion, a P/E ratio of -22.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company has a fifty day moving average of $194.32 and a 200 day moving average of $188.98.

BeiGene (NASDAQ:BGNE) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. During the same period in the prior year, the company earned $2.01 EPS. The firm’s revenue was up 28.2% compared to the same quarter last year. On average, equities analysts anticipate that BeiGene will post -5.64 earnings per share for the current year.

Insider Buying and Selling at BeiGene

In other news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the sale, the director now directly owns 791,493 shares of the company’s stock, valued at approximately $148,222,894.11. This trade represents a 56.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Xiaodong Wang sold 40,468 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total transaction of $7,692,966.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,119,245 shares of company stock worth $209,700,084. 7.43% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BeiGene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after purchasing an additional 75 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of BeiGene in the 3rd quarter worth approximately $36,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of BeiGene in the 3rd quarter worth approximately $67,000. SG Americas Securities LLC bought a new position in BeiGene during the 3rd quarter valued at approximately $105,000. Finally, PFG Investments LLC purchased a new position in BeiGene during the third quarter valued at $210,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.